Cite
APA Citation
Krebs, M., Majem, M., Felip, E., Forster, M., Doger, B., Clay, T., Carcereny, E., Peguero, J., Horn, L., Bajaj, P., Roxburgh, P., Brignone, C., Mueller, C., & Triebel, F. (n.d.). 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). Journal for immunotherapy of cancer, 8, A839. http://access.bl.uk/ark:/81055/vdc_100144731627.0x000001